Seeking Alpha
All posts from Seeking Alpha
Seeking Alpha in Seeking Alpha - Read, Decide, Invest.,

IPO Preview: Carbylan Therapeutics

Based in Palo Alto, CA, Carbylan Therapeutics (CBYL) scheduled a $75 million IPO on Nasdaq with a market capitalization of $198 million at a price range midpoint of $13 for Wednesday, Feb. 4, 2015.

The full IPO calendar is available at IPOpremium

SEC Documents

Manager, Joint-managers: Leerink Partners
Co-managers: JMP Securities/ Wedbush PacGrow Life Sciences

End of lockup (180 days): Monday, August 3, 2015
End of 25-day quiet period: Monday, March 2, 2015

CBYL is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel and proprietary combination therapies that address significant unmet medical needs.

CBYL's initial focus is on the development of Hydros-TA, its proprietary, potentially best-in-class intra-articular, or IA, injectable product candidate to treat pain associated with osteoarthritis, or OA, of the knee.


Accumulated deficit ($mm)




Per share dilution





Valuation Ratios

Mrkt Cap ($mm)